Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 04 Aug 2022
TGA says go to BioMarin for Voxzogo
4 August 2022 - Vosoritide is a modified type C natriuretic peptide. ...
Posted by Michael Wonder on 04 Aug 2022
Pear Therapeutics and Cove Behavioral Health to provide patients access to prescription digital therapeutic for the treatment of opioid use disorder
3 August 2022 - Pear Therapeutics announced today that Cove Behavioral Health will provide access to Pear’s FDA authorised PDT reSET-O ...
Posted by Michael Wonder on 04 Aug 2022
There is an effective treatment for monkeypox, but it’s hard to get
29 July 2022 - A smallpox antiviral that’s effective against monkeypox is tied up in red tape, and gay health advocates ...
Posted by Michael Wonder on 04 Aug 2022
Economic evaluation of genomic/genetic tests: a review and future directions
1 August 2022 - It has been suggested that health economists need to improve their methods in order to meet the ...
Posted by Michael Wonder on 03 Aug 2022
AbbVie wins appeal in antitrust case over Humira 'patent thicket'
3 August 2022 - A U.S. appeals court on Monday affirmed that AbbVie Inc did not unlawfully block competition by ...
Posted by Michael Wonder on 03 Aug 2022
Seven years ago I ditched my private hospital cover. This is why I’m now getting it back.
4 August 2022 - Seven years ago I called my private health company and told them I was done. ...
Posted by Michael Wonder on 03 Aug 2022
Connecting electronic health records to clinical trials: how to embrace the promise of real world data
3 August 2022 - We all know that real world data from electronic health records could boost clinical trial efficiency ...
Posted by Michael Wonder on 03 Aug 2022
Bupa patients worried Ramsay Health Care hospital dispute will leave them out of pocket
3 August 2022 - A funding dispute between one of Australia's largest private hospital operators and a major insurer could ...
Posted by Michael Wonder on 03 Aug 2022
U.S. prescription drug market lacks certain competitive features: case of biosimilars
3 August 2022 - In a legal ruling reported yesterday, a 7th Circuit Court Federal Judge, Frank Easterbrook, affirmed dismissal of ...
Posted by Michael Wonder on 03 Aug 2022
Fresenius Kabi’s biologics license application for biosimilar candidate tocilizumab accepted for review by the FDA
1 August 2022 - Fresenius Kabi announced today that the U.S. FDA has accepted for review the company’s 351(k) biologics ...
Posted by Michael Wonder on 03 Aug 2022
Amylyx Pharmaceuticals announces FDA Advisory Committee will reconvene to review new drug application for AMX0035 for the treatment of ALS
3 August 2022 - Amylyx Pharmaceuticals today announced that the U.S. FDA Peripheral and Central Nervous System Drugs Advisory Committee will ...
Posted by Michael Wonder on 03 Aug 2022
Supply a factor in restricting COVID vaccines for babies and toddlers
3 August 2022 - Most parents of babies and toddlers will not be able to access a COVID vaccine approved ...
Posted by Michael Wonder on 03 Aug 2022
AnHeart Therapeutics receives FDA breakthrough therapy designation for taletrectinib in ROS1 positive non-small-cell lung cancer
3 August 2022 - FDA breakthrough designation reinforces significant unmet need in the treatment of this highly aggressive cancer. ...
Posted by Michael Wonder on 03 Aug 2022
COVID-19 vaccination for children aged 6 months to under 5 years
3 August 2022 - The Albanese Government has accepted a recommendation from the Australian Technical Advisory Group on Immunisation to make ...
Posted by Michael Wonder on 03 Aug 2022
MediWound announces US FDA acceptance of biologics license application for NexoBrid for the treatment of severe thermal burns
3 August 2022 - Prescription Drug User Fee Act target date of 1 January 2023. ...